Y. Chalandon

Discipline

Psychologie (2) Economies et finances (1)

Type de document

Articles (10) Recensions (3)

Co-auteur

Date

Source

Mot-clé

Treatment (8) Patients (7) Patients (6) survie (5) Survival (5) Rates (4) Human beings (4) Rates (4) Number (4) puits (3) risque (3) analyse (3) adulte (3) procès (3) Cases (3) Risk (3) Population (3) Arm (3) Cases (3) Analysis (3) adulte (3) thérapie (2) mortalité (2) dose (2) âge (2) Mortality (2) Diagnosis (2) Chemotherapy (2) Cell transplantation (2) Time (2)

Documents écrit par Y. Chalandon (10) | parle de Y. Chalandon (0)

Inhibiteurs des Janus kinases : nouvelles perspectives pour la médecine de précision ? [Janus kinase inhibitors : new perspectives for precision medicine ?]
J. Tachet et al. (19 oct. 2022)
Frequency and causes of antifungal treatment changes in allogeneic haematopoïetic cell transplant recipients with invasive mould infections.
R.S. Roth et al.
Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS.
J. Janssen et al. (7 févr. 2021)
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS.
G. Huls et al. (22 sept. 2020)
γ-Catenin-Dependent Signals Maintain BCR-ABL1+ B Cell Acute Lymphoblastic Leukemia.
N. Luong-Gardiol et al. (15 avr. 2019)
Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016.
J.R. Passweg et al. (2018)
Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.
V. Gotta et al. (2014)
Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients.
F. Buchegger et al. (2013)
Haematopoietic stem cell transplantation: activity in Switzerland compared with surrounding European countries.
J.R. Passweg et al. (2013)
Suivi thérapeutique de l'imatinib
V. Gotta et al. (2010)